central nerve system tumor
Conditions
Interventions
CAR-T:CAR-T cell infusion
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. IL-13Ra2, B7H3, EGFRvIII or CD19-positive glioblastoma or lymphoma in brain is verified by immunohistochemical analysis or PCR; 2. Diseace progression is observed after standard surgeryradiotherapy and chemotherapy treatment, with no other effective therapy available; 3. The patient is not under glucocorticoid therapy, or has stop using glucocorticoid for over 5 days; 4. According to RECIST1.1 criteria, measurable focus is observed in imaging examination; 5. Patient gets a Karnofsky appraisal > 60 scores; 6. Regardless of gender, the patient should be over 18 years old; 7. Estimated lifetime should be over 3 months; 8. Important viscera function: (1) Ejection fraction is over 50% according to cardiac ultrasound; (2) No significant change is found in electrocardiogram; (3) Oxygen saturation is higher than 90%; 9. Hematological test and biochemical detection: (1) Neutrophil count > 1000/ml with no colony stimulation factors used; (2) White blood cell count > 2000/ml; (3) Blood platelet count > 100,000/ml; (4) Hemoglobin > 8.0g. When patients are under this criteria, transfusion may be under consideration; (5) ALT/AST < 2.5 folds of the normal maximum index; (6) Total bilirubin < 1.5 folds of the normal maximum index; (7) Creatinine < 1.6mg/ml; 10. All of the participant should have the willing and ability to sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) The patient gets a history of immunological disease, or is under the use of glucocorticoid drugs or other immunosuppressive therapy due to other disease. (2) The patient is confronted with irrelievable hypoxia, hypertension, heart failure, serious arrhythmia, asthma, respiratory failure or nephropathy requiring dialysis. (3) The patient is under progressive infection, HIV infection or progressive hepatitis B or C. (4) The patient is under seizures out of control, or progressive brain disease with significant clinical features. (5) The patient gets other progressive tumors. (6) The patient is under pregnancy or lactation. (7) The patient refuses to take contraception during treatment and the next year following. (8) The patient has already joined another clinical trial. (9) The patient is a male with reproduction intention. (10) There exist other factors assessed by researchers that affect patients participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRI;PET-CT;cytokine;liver fuction;kidney fuction;blood pressure;body temperature;intracranial pressure; | — |
Countries
China
Contacts
Public ContactLiangxue Zhou
Neurosurgery Department, West China Hospital, Sichuan University
Outcome results
None listed